Researchers have identified a significant risk factor that affects the prognosis of people with chronic thromboembolic pulmonary hypertension (CTEPH) in a large 26-year study. They found that elevated left ventricular filling pressure (LVFP), a measure of left heart function, was common in patients and predicted worse outcomes. Pulmonary hypertension…
Referral to a specialized chronic thromboembolic pulmonary hypertension (CTEPH) center for follow-up treatment after a pulmonary embolism (PE) — a blood clot that blocks an artery in the lungs — is more likely if patients live closer to the center and have access to a primary healthcare provider, a…
Four genes associated with the metabolism of copper in the body have been identified as potential diagnostic biomarkers of pulmonary arterial hypertension (PAH), a new study reports. Researchers used computer software tools to look for specific genes tied to copper metabolism that may serve as less-invasive markers for diagnosing…
Adding sotatercept to standard therapies significantly improved the six-minute walking distance by more than 40 meters (131 feet) compared with a placebo among adults with pulmonary arterial hypertension (PAH). This finding met the primary goal of STELLAR, a Phase 3 clinical trial evaluating the impact of 24 weeks, or…
An investigational once-daily therapy, a single tablet combining macitentan and tadalafil, significantly improved pulmonary blood flow compared with macitentan or tadalafil alone in pulmonary arterial hypertension (PAH) patients taking part in the Phase 3 A DUE study. Because these medications target different PAH-related pathways, current guidelines recommend initially treating…
The accumulation of aggrecan, a protein found abundantly in cartilage, may be an early response to injury in the lungs of people with idiopathic pulmonary arterial hypertension, a study suggests. Aggrecan accumulated preferentially in blood vessel lesions marked by high blood pressure in the lungs of idiopathic PAH (IPAH)…
Team PHenomenal Hope — Team PH — a nonprofit organization seeking to raise awareness about pulmonary hypertension (PH), has launched an educational website for people newly diagnosed or who are living with the rare disease. The site, called Learn Live Breathe PH, was launched Feb. 28 in…
Treatment with Pulnovo Medical’s pulmonary artery denervation (PADN) device significantly reduced the risk of clinical worsening among people with pulmonary arterial hypertension (PAH) in a clinical trial, according to new data announced by the company. Chen Shaoliang, a professor at Nanjing First Hospital of Nanjing Medical University in China,…
People with pulmonary hypertension (PH) who took dipyrone to help manage pain were at a significantly lower risk of assisted ventilation and hospitalization then patients not using this prescription painkiller, according to a large, real-world study. Animal work suggests that dipyrone lowers blood pressure in the pulmonary arteries, and a…
The development program of AER-901, Aerami Therapeutics’ inhaled formulation of imatinib, will include pulmonary hypertension associated with interstitial lung disease (PH-ILD). According to the company, data from a completed Phase 1 clinical trial support the progression of AER-901 into Phase 2 trials for pulmonary arterial hypertension (PAH)…
Treatment with C75, an inhibitor of an enzyme called fatty acid synthase (FAS), partially reversed disease processes in a mouse model of pulmonary arterial hypertension (PAH), a study reports. C75 benefits may be linked to changes in pathways involved in cell proliferation and inflammation, among other processes, “thus inhibition…
Pulmonary endarterectomy (PEA) and balloon pulmonary angioplasty (BPA) — two treatment approaches for chronic thromboembolic pulmonary hypertension (CTEPH) — significantly improved blood flow dynamics and functional capacity in patients given either procedure, a study from Norway reported. PEA was more effective at reducing pressure and resistance in the lungs’…
Get regular updates to your inbox.
